Description
Mal-PEG8-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a maleimide PEG8 moiety, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. Mal is reactive with thiol group of antibody.
Uses
Mal-PEG8-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162)[1].
References
[1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. DOI:
10.1038/nrd.2016.268
